SNDL Past Earnings Performance

Past criteria checks 0/6

SNDL's earnings have been declining at an average annual rate of -20.3%, while the Pharmaceuticals industry saw earnings growing at 6.5% annually. Revenues have been growing at an average rate of 74.8% per year.

Key information

-20.3%

Earnings growth rate

51.7%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate74.8%
Return on equity-18.8%
Net Margin-23.4%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

SNDL Inc.'s (NASDAQ:SNDL) Revenues Are Not Doing Enough For Some Investors

Jan 15
SNDL Inc.'s (NASDAQ:SNDL) Revenues Are Not Doing Enough For Some Investors

SNDL Inc.'s (NASDAQ:SNDL) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jun 22
SNDL Inc.'s (NASDAQ:SNDL) 25% Dip In Price Shows Sentiment Is Matching Earnings

Are Investors Undervaluing SNDL Inc. (NASDAQ:SNDL) By 22%?

Dec 12
Are Investors Undervaluing SNDL Inc. (NASDAQ:SNDL) By 22%?

SNDL Starting To Stand Out Among Canadian Cannabis Players

Aug 05

Sundial Growers whipsaws ahead of shareholder meeting on reverse stock split

Jul 20

Sundial Growers Looking Bullish As Revenue Growth From Acquisitions Increases

May 19

Sundial Growers Doubles Revenue With Spiritleaf Acquisition And Reports Positive EBITDA For Q4-2021

Apr 28

Sundial Growers' Cash War Chest And Its Bid To Avoid Another Dilution

Mar 21

Sundial Growers Stock: What To Watch For Going Into 2022

Dec 28

Taking A Look At The Canadian Cannabis Penny Stock: Sundial Growers

Nov 04

Sundial Moves On Alcanna Acquisition And Nova Cannabis Investment

Oct 12

Sundial: A Speculative Buy On The Restructure

Sep 25

Insight Into Sundial Growers' Q2 2021 Earnings Report

Aug 24

Sundial: Can The Recent Acquisition Turn This Story Around?

Jul 23

Evaluating Sundial Growers' Acquisition Of Inner Spirit And Partnership With SAF Group

Jul 01

Sundial Growers regains Nasdaq compliance

Jun 16

Sundial Growers: Finding Ways To Spend That $1.1B Cash

Jun 01

Sundial Growers boosts stake in The Valens Company

May 04

Sundial Growers: The Luckiest Cannabis Stock Of 2021

Feb 04

Cannabis producer Sundial up more than 17% following 14% loss prior day

Feb 03

Sundial Growers trades in red on pricing $74.5M offering

Feb 02

Sundial Growers raises $100M capital through registered offering

Jan 29

Sundial launched premium concentrates products under Top Leaf brand

Jan 12

Sundial Growers: A Busy End To 2020 Indicates Potential Strategic Expansion

Jan 11

After another catalyst, Motley Fool sizes up cannabis sector

Jan 08

Sundial, HEXO lead out big gains in cannabis sector

Jan 06

Seeking Alpha Catalyst Watch

Dec 31

Sundial acquires C$59M special purpose vehicle

Dec 30

Sundial cheers concentrates license agreement with Simply Solventless

Dec 28

Sundial prepays C$50M of senior secured non-revolving term credit facility

Dec 15

Sundial Growers: Not Out Of The Weeds Yet

Nov 23

Sundial Growers Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 12

Sundial Growers misses on revenue

Nov 11

Revenue & Expenses Breakdown
Beta

How SNDL makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:SNDL Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 23901-2112211
30 Jun 23894-2872132
31 Mar 23897-3311962
31 Dec 22712-3351582
30 Sep 22495-2661243
30 Jun 22278-151882
31 Mar 2264-130602
31 Dec 2156-227552
30 Sep 2147-228502
30 Jun 2146-316491
31 Mar 2157-296450
31 Dec 2061-200460
30 Sep 2062-170591
30 Jun 2077-184701
31 Mar 2076-164803
31 Dec 1964-143862
30 Sep 1949-156722
30 Jun 1921-84542
31 Mar 191-77370
31 Dec 180-68220
28 Feb 180-1390

Quality Earnings: SNDL is currently unprofitable.

Growing Profit Margin: SNDL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SNDL is unprofitable, and losses have increased over the past 5 years at a rate of 20.3% per year.

Accelerating Growth: Unable to compare SNDL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNDL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).


Return on Equity

High ROE: SNDL has a negative Return on Equity (-18.78%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.